Addrenex Obtains Early-Stage Narcolepsy Drug from SK Holdings
Phase II studies are expected to begin later this year.
Addrenex Pharmaceuticals will obtain rights to ADX-N05 from SK Holdings, a South Korean company, to expand its pipeline of adrenergic-regulating drugs. ADX-N05 is being designed to treat narcolepsy and possibly other neurologic conditions.
Phase II testing of ADX-N05 is expected to begin this year for narcolepsy. The company says future trials may be instituted for the use of the compound as an adjunct therapy for depression.
The compound joins three other products in clinical trials. Clonicel is in a Phase III program for ADHD and ADX415 is in a Phase II hypertension study and a Phase I trial for menopausal flushing. ADX415 is partnered with Sciele Pharma. Sympres has been submitted for approval in hypertension, and an extended release version of the drug is being investigated in Phase II study for the same indication .